Skip to content

Effect of Adjuvant Hyperbaric Oxygen Therapy on Bells Palsy Outcome

Effect of Adjuvant Hyperbaric Oxygen Therapy on Bells Palsy Outcome

Status
Withdrawn
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03457025
Enrollment
0
Registered
2018-03-07
Start date
2019-08-31
Completion date
2020-06-30
Last updated
2020-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bell Palsy

Keywords

Oxygen Therapy, Bells Palsy

Brief summary

This is a randomized, single blinded, non-placebo controlled that will compare one group of Bells Palsy patients receiving the current standard of care including oral corticosteroids and oral antivirals against an experimental group receiving the current standard of care in addition to hyperbaric oxygen therapy. Outcome assessment will be based on both objective analyses of facial movements as well as subjective quality of life scales.

Interventions

Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg

DRUGOral antivirals

acyclovir 400mg: one pill 4 times daily for 7 days

DEVICEHyperbaric Oxygen Therapy

2.4atm administered for twice daily dives for 5 days, 10 dives total. To be begun in the first 1 week after onset of paralysis.

Sponsors

NYU Langone Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years or older exhibiting unilateral facial paralysis progressing to completion in 4 days or less.

Exclusion criteria

* No patients from vulnerable populations as listed above will be included. * Subjects must be able to travel to NYULMC continually during the first 12 months following enrollment. * During the initial visit candidates must have no associated clinical signs or symptoms consistent with other causes of facial palsy. This includes but is not limited to: auricular papules, skin rashes, parotid masses, craniofacial trauma, and the presence of other cranial or distal neuropathies excluding facial numbness, change in taste, and/or hyperacusis. * Patients with atypical presentations will be referred for cross-sectional imaging and excluded. * Patients with histories consistent with possible recent tick exposure, rashes, headaches, or excessive fatigue will be serologically tested for Lyme disease and excluded if it returns positive. * Pneumothorax within the last two years is the only absolute medical

Design outcomes

Primary

MeasureTime frame
Change in the percentage of subjects that return to baseline facial function 1 year following the onset of paralysis Standard of Care Group3, 6 and 12 months
Change in the percentage of subjects that return to baseline facial function 1 year following the onset of paralysis Standard of Care + Hyperbaric Oxygen Therapy on Bells Palsy (HBOT) Group3, 6 and 12 months

Secondary

MeasureTime frameDescription
Facial Clinimetric Evaluation Scale (FaCE) Score Standard of Care Group3, 6 and 12 monthsUsed to assess facial impairment and disability after facial paralysis. It involves 15 statements, each using a five-item Likert scale. A participant circles the most appropriate response to a given statement, whereby 1 corresponds to the lowest function and 5 corresponds to the highest function. Statements are grouped into six independent domains: social function, facial movement, facial comfort, oral function, eye comfort, and lacrimal control. A score from 0 (worst) to 100 (best) is calculated.
Facial Clinimetric Evaluation Scale (FaCE) Score Standard of Care + HBOT3, 6 and 12 monthsUsed to assess facial impairment and disability after facial paralysis. It involves 15 statements, each using a five-item Likert scale. A participant circles the most appropriate response to a given statement, whereby 1 corresponds to the lowest function and 5 corresponds to the highest function. Statements are grouped into six independent domains: social function, facial movement, facial comfort, oral function, eye comfort, and lacrimal control. A score from 0 (worst) to 100 (best) is calculated.
Short Form 36 (SF-36) Score Standard of Care Group3, 6 and 12 monthsAs part of the Medical Outcomes Study (MOS), a multi-year, multi-site study to explain variations in patient outcomes, RAND developed the 36-Item Short Form Health Survey (SF-36). The eight sections are: vitality physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health
Facial Disability Index (FDI) Score Standard of Care + HBOT3, 6 and 12 monthsAssesses facial neuromuscular dysfunction. Consists of 10 questions regarding physical function scoring difficulty on a scale of 2-5; 5 being no difficulty and 2 being much difficulty
Facial Disability Index (FDI) Score Standard of Care Group3, 6 and 12 monthsAssesses facial neuromuscular dysfunction. Consists of 10 questions regarding physical function scoring difficulty on a scale of 2-5; 5 being no difficulty and 2 being much difficulty
Short Form 36 (SF-36) Score Standard of Care + HBOT3, 6 and 12 monthsAs part of the Medical Outcomes Study (MOS), a multi-year, multi-site study to explain variations in patient outcomes, RAND developed the 36-Item Short Form Health Survey (SF-36). The eight sections are: vitality physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026